What is Centese?
Centese is at the forefront of transforming surgical drainage technology, particularly for cardiothoracic procedures. Their flagship product, Thoraguard, represents a significant advancement, offering a digital drainage system that provides precise data monitoring to aid clinical decision-making. By focusing on improving patient recovery and streamlining workflows for critical care teams, Centese aims to deliver intelligence and efficacy in a traditionally underserved area of surgical care. The company's commitment to safety and data-driven insights positions it as a key innovator in the medical technology landscape.
How much funding has Centese raised?
Centese has raised a total of $15M across 1 funding round:
Series B
$15M
Series B (2023): $15M with participation from MedTech Venture Partners
Key Investors in Centese
MedTech Venture Partners
MedTech Venture Partners is a venture capital firm dedicated to advancing the medical technology sector. They provide crucial financial backing and strategic guidance to innovative companies, aiming to foster growth and development within the healthcare industry.
What's next for Centese?
The recent major strategic investment signals a pivotal growth phase for Centese. This capital infusion is expected to accelerate product development, expand market reach, and further solidify its position in the competitive medical device sector. With a clear focus on enhancing clinical decision-making and patient recovery through its digital drainage solutions, Centese is poised for significant expansion. The company's trajectory suggests a strong emphasis on scaling operations and potentially exploring new applications for its technology, driven by the strategic backing from key industry players.
See full Centese company page
